Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patients

Roger Bedimo, Minhee Kang, Pablo Tebas, Edgar T. Overton, Kimberly Hollabaugh, Grace Mccomsey, Debika Bhattacharya, Christopher Evans, Todd T. Brown, Babafemi Taiwo

Research output: Contribution to journalArticle

4 Scopus citations


HIV/hepatitis C virus (HCV) patients have a 3-fold increased fracture incidence compared to uninfected patients. The impact of HCV therapy on bone health is unclear. We evaluated bone turnover markers (BTM) in well-controlled (HIV RNA

Original languageEnglish (US)
Pages (from-to)325-328
Number of pages4
JournalAIDS Research and Human Retroviruses
Issue number4
Publication statusPublished - Apr 1 2016


ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this